stage II childhood Hodgkin lymphoma
Showing 1 - 25 of >10,000
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity
Completed
- Childhood Favorable Prognosis Hodgkin Lymphoma
- +5 more
- radiation therapy
- +11 more
-
Arcadia, CaliforniaChildren's Oncology Group
Mar 26, 2021
Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
-
Cologne, Germany1st Department of Medicine, Cologne University Hospital
Sep 19, 2023
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Completed
- Hematopoietic/Lymphoid Cancer
- +135 more
- beclomethasone dipropionate
- +4 more
-
Hackensack, New Jersey
- +1 more
Feb 1, 2021
Classical Hodgkin Lymphoma Trial in Guangzhou (Zimberelimab 240mg)
Recruiting
- Classical Hodgkin Lymphoma
- Zimberelimab 240mg
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Ce
Jun 15, 2023
Classical Hodgkin Lymphoma Trial in Cologne (Tislelizumab)
Not yet recruiting
- Classical Hodgkin Lymphoma
-
Cologne, Germany1st Department of Medicine, Cologne University Hospital
Aug 5, 2022
Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United
Active, not recruiting
- Ann Arbor Stage IB Hodgkin Lymphoma
- +10 more
- Brentuximab Vedotin
- Nivolumab
-
Palo Alto, California
- +8 more
Jul 20, 2022
Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)
Recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- SHR2554+ SHR1701
- SHR-1701
-
Beijing, Beijing, ChinaHan wei dong
Jun 14, 2023
Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)
Not yet recruiting
- Non-hodgkin's Lymphoma
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Sep 27, 2023
Classic Hodgkin Lymphoma Trial (Concurrent penpulimab and AVD, Sequential penpulimab and AVD)
Not yet recruiting
- Classic Hodgkin Lymphoma
- Concurrent penpulimab and AVD
- Sequential penpulimab and AVD
- (no location specified)
Jul 10, 2023
B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- SHR-A1912; R-Chemo
- (no location specified)
Oct 23, 2023
Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)
Active, not recruiting
- Classical Hodgkin Lymphoma
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Nov 28, 2022
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Non Hodgkin Lymphoma Trial in Philadelphia (Pembrolizumab)
Recruiting
- Non Hodgkin Lymphoma
-
Philadelphia, PennsylvaniaAbamson Cancer Center of the University of Pennsylvania
Jan 9, 2023
Classical Hodgkin Lymphoma Trial in Cologne (Nivolumab, Adriamycin, Vinblastine)
Active, not recruiting
- Classical Hodgkin Lymphoma
- Nivolumab
- +3 more
-
Cologne, GermanyUniversity Hospital of Cologne
Aug 5, 2022
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 18, 2022
CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)
Terminated
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell
Completed
- AIDS-related Diffuse Large Cell Lymphoma
- +8 more
- cyclophosphamide
- +7 more
-
Eldoret, Kenya
- +1 more
Sep 12, 2022
HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,
Active, not recruiting
- HIV Infection
- +3 more
- brentuximab vedotin
- +3 more
-
Clamart, France
- +5 more
Aug 11, 2022
AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in France, United
Active, not recruiting
- AIDS-Related Hodgkin Lymphoma
- +11 more
- Brentuximab Vedotin
- +4 more
-
La Jolla, California
- +27 more
Jul 27, 2022
Non-hodgkin Lymphoma Trial (HY004)
Not yet recruiting
- Non-hodgkin Lymphoma
- HY004
- (no location specified)
Aug 21, 2023
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Acute Lymphoblastic Leukemia, Hodgkin Disease, Allogeneic Stem Cell Transplantation Trial in Erlangen (Low-field magnetic
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- Low-field magnetic resonance imaging
- +3 more
-
Erlangen, Bavaria, GermanyDepartment of Pediatrics and Adolescent Medicine
Oct 23, 2023